DRI Healthcare Trust (TSE:DHT.UN) Stock Price Expected to Rise, National Bankshares Analyst Says

DRI Healthcare Trust (TSE:DHT.UN) had its price objective raised by equities research analysts at National Bankshares from C$18.00 to C$18.50 in a research note issued on Thursday,BayStreet.CA reports. The brokerage currently has an “outperform” rating on the stock. National Bankshares’ price objective would indicate a potential upside of 46.36% from the company’s current price.

Separately, CIBC increased their price target on DRI Healthcare Trust from C$16.00 to C$17.00 and gave the company an “outperform” rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, DRI Healthcare Trust currently has a consensus rating of “Moderate Buy” and an average price target of C$18.07.

DRI Healthcare Trust Stock Up 0.6%

DHT.UN stock opened at C$12.64 on Thursday. The business’s 50-day moving average is C$11.66 and its two-hundred day moving average is C$11.99. DRI Healthcare Trust has a 1 year low of C$10.39 and a 1 year high of C$16.26.

About DRI Healthcare Trust

DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.